company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:05:39+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,233000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:05:39+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,233000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:05:39+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,233000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:05:39+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,879000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:05:39+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4965000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:05:39+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5844000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:05:39+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5611000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:05:39+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:05:39+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,0.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:05:39+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:05:39+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5611000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:05:39+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5611000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:05:39+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5611000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:05:39+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5611000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:05:39+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,2200000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:05:39+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.52
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:05:39+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,2200000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:05:39+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.52
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:05:39+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,2225596.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:05:39+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.52
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 07:53:39+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,133000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 07:53:39+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,133000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 07:53:39+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,133000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 07:53:39+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,943000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 07:53:39+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6060000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 07:53:39+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7003000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 07:53:39+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-6870000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 07:53:39+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 07:53:39+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,0.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 07:53:39+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 07:53:39+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6870000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 07:53:39+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6870000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 07:53:39+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6870000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 07:53:39+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6869000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 07:53:39+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,2400000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 07:53:39+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.86
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 07:53:39+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,2400000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 07:53:39+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.86
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 07:53:39+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,2404080.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 07:53:39+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.86
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q4,2013-01-01,2013-12-31,2016-03-15 16:13:37+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,387000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q4,2013-01-01,2013-12-31,2016-03-15 16:13:37+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,387000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q4,2013-01-01,2013-12-31,2016-03-15 16:13:37+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,387000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q4,2013-01-01,2013-12-31,2016-03-15 16:13:37+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5885000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q4,2013-01-01,2013-12-31,2016-03-15 16:13:37+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,28452000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q4,2013-01-01,2013-12-31,2016-03-15 16:13:37+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,34337000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q4,2013-01-01,2013-12-31,2016-03-15 16:13:37+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-33950000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q4,2013-01-01,2013-12-31,2016-03-15 16:13:37+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q4,2013-01-01,2013-12-31,2016-03-15 16:13:37+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,3000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q4,2013-01-01,2013-12-31,2016-03-15 16:13:37+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q4,2013-01-01,2013-12-31,2016-03-15 16:13:37+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,3000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q4,2013-01-01,2013-12-31,2016-03-15 16:13:37+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-33947000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q4,2013-01-01,2013-12-31,2016-03-15 16:13:37+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-33947000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q4,2013-01-01,2013-12-31,2016-03-15 16:13:37+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-33947000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q4,2013-01-01,2013-12-31,2016-03-15 16:13:37+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-33947000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q4,2013-01-01,2013-12-31,2016-03-15 16:13:37+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,6100000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q4,2013-01-01,2013-12-31,2016-03-15 16:13:37+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-5.59
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q4,2013-01-01,2013-12-31,2016-03-15 16:13:37+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,6100000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q4,2013-01-01,2013-12-31,2016-03-15 16:13:37+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-5.59
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q4,2013-01-01,2013-12-31,2016-03-15 16:13:37+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,6067679.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2013.0,Q4,2013-01-01,2013-12-31,2016-03-15 16:13:37+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-5.59
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:02:18+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,171000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:02:18+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,171000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:02:18+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,171000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:02:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2904000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:02:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10979000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:02:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13883000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:02:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13712000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:02:18+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,18000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:02:18+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:02:18+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,18000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:02:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-13694000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:02:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13694000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:02:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13694000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:02:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13694000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:02:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,29800000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:02:18+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.46
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:02:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,29800000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:02:18+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.46
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:02:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,29606683.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:02:18+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.46
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 07:01:16+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 07:01:16+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 07:01:16+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,21000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 07:01:16+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3310000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 07:01:16+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13159000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 07:01:16+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,16469000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 07:01:16+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-16448000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 07:01:16+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,17000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 07:01:16+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 07:01:16+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,17000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 07:01:16+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-16431000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 07:01:16+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16431000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 07:01:16+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16431000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 07:01:16+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-16431000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 07:01:16+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,29900000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 07:01:16+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.55
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 07:01:16+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,29900000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 07:01:16+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.55
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 07:01:16+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,29659457.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 07:01:16+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.55
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:01:02+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:01:02+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:01:02+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,21000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:01:02+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3814000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:01:02+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15951000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:01:02+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19765000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:01:02+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-19744000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:01:02+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,20000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:01:02+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:01:02+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,20000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:01:02+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19724000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:01:02+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19724000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:01:02+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19724000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:01:02+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-19724000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:01:02+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,32300000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:01:02+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.61
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:01:02+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,32300000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:01:02+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.61
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:01:02+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,32558646.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 07:01:02+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.61
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,16000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,16000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,16000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5920000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,20038000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,25958000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-25942000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,42000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-27000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,14000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-25928000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-25928000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-25928000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-25928000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,31200000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.81
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,31200000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.81
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,31135694.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.81
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:08:19+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5399000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:08:19+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,20751000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:08:19+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,26150000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:08:19+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-26150000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:08:19+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,141000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:08:19+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-58000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:08:19+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,83000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:08:19+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-26067000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:08:19+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-26067000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:08:19+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-26067000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:08:19+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-26067000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:08:19+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,35200000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:08:19+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.74
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:08:19+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,35200000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:08:19+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.74
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:08:19+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,35317181.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:08:19+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.74
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:06:53+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,150000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:06:53+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,150000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:06:53+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,150000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:06:53+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6157000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:06:53+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,27006000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:06:53+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,33163000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:06:53+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-33013000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:06:53+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,267000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:06:53+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,51000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:06:53+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,318000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:06:53+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-32695000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:06:53+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-32695000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:06:53+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-32695000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:06:53+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-32695000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:06:53+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,35500000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:06:53+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.92
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:06:53+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,35500000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:06:53+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.92
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:06:53+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,35697012.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:06:53+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.92
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:25:55+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,75000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:25:55+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,75000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:25:55+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,75000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:25:55+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4762000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:25:55+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,25923000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:25:55+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,30685000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:25:55+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-30610000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:25:55+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,239000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:25:55+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:25:55+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,237000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:25:55+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-30373000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:25:55+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-30373000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:25:55+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-30373000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:25:55+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-30373000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:25:55+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,35700000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:25:55+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.85
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:25:55+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,35700000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:25:55+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.85
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:25:55+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,35708739.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:25:55+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.85
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,25000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,25000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,25000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5264000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,24064000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,29328000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-29303000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,250000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,7000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,257000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-29046000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-29046000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-29046000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-29046000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,35600000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.81
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,35600000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.81
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,35619506.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.81
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:07:58+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:07:58+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5554000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:07:58+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,21795000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:07:58+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,27349000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:07:58+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-27349000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:07:58+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,286000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:07:58+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,4000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:07:58+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,290000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:07:58+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-27059000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:07:58+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:07:58+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-27059000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:07:58+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-27059000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:07:58+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-27059000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:07:58+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,36100000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:07:58+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.75
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:07:58+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,36100000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:07:58+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.75
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:07:58+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,35878502.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:07:58+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.75
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:06:53+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,59000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:06:53+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,59000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:06:53+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,59000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:06:53+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5956000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:06:53+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,24579000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:06:53+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,30535000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:06:53+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-30476000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:06:53+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,329000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:06:53+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-11000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:06:53+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,318000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:06:53+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-30158000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:06:53+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-30158000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:06:53+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-30158000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:06:53+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-30158000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:06:53+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,35900000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:06:53+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.84
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:06:53+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,35900000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:06:53+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.84
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:06:53+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,35956470.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:06:53+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.84
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q3,2016-07-01,2016-09-30,2016-11-07 16:25:55+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,48000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q3,2016-07-01,2016-09-30,2016-11-07 16:25:55+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,48000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q3,2016-07-01,2016-09-30,2016-11-07 16:25:55+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,48000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q3,2016-07-01,2016-09-30,2016-11-07 16:25:55+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5897000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q3,2016-07-01,2016-09-30,2016-11-07 16:25:55+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,19893000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q3,2016-07-01,2016-09-30,2016-11-07 16:25:55+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,25790000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q3,2016-07-01,2016-09-30,2016-11-07 16:25:55+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-25742000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q3,2016-07-01,2016-09-30,2016-11-07 16:25:55+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,311000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q3,2016-07-01,2016-09-30,2016-11-07 16:25:55+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,6000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q3,2016-07-01,2016-09-30,2016-11-07 16:25:55+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,317000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q3,2016-07-01,2016-09-30,2016-11-07 16:25:55+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-25425000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q3,2016-07-01,2016-09-30,2016-11-07 16:25:55+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-25425000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q3,2016-07-01,2016-09-30,2016-11-07 16:25:55+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-25425000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q3,2016-07-01,2016-09-30,2016-11-07 16:25:55+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-25425000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q3,2016-07-01,2016-09-30,2016-11-07 16:25:55+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,36800000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q3,2016-07-01,2016-09-30,2016-11-07 16:25:55+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.69
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q3,2016-07-01,2016-09-30,2016-11-07 16:25:55+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,36800000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q3,2016-07-01,2016-09-30,2016-11-07 16:25:55+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.69
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q3,2016-07-01,2016-09-30,2016-11-07 16:25:55+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,36819329.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q3,2016-07-01,2016-09-30,2016-11-07 16:25:55+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.69
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,47000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,47000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,47000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6541000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,20671000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,27212000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-27165000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,358000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,11000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,369000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-26796000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,139000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-26935000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-26935000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-26935000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,37500000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.64
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,37500000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.64
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,37523051.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.64
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:06:51+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,68000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:06:51+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,68000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:06:51+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,68000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:06:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6264000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:06:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,24083000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:06:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,30347000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:06:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-30279000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:06:51+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,400000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:06:51+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-15000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:06:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,385000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:06:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-29894000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:06:51+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,23000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:06:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-29917000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:06:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-29917000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:06:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-29917000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:06:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42100000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:06:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.71
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:06:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42100000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:06:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.71
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:06:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,41894796.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:06:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.71
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:18:59+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:18:59+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:18:59+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:18:59+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6635000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:18:59+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,23120000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:18:59+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,29755000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:18:59+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-29752000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:18:59+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,412000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:18:59+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-29000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:18:59+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,383000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:18:59+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-29369000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:18:59+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,18000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:18:59+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-29387000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:18:59+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-29387000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:18:59+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-29387000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:18:59+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,45900000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:18:59+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.64
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:18:59+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,45900000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:18:59+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.64
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:18:59+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,45831239.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 17:18:59+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.64
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:12:06+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:12:06+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5818000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:12:06+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,25237000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:12:06+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,31055000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:12:06+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-31055000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:12:06+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,454000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:12:06+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-26000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:12:06+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,428000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:12:06+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-30627000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:12:06+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,13000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:12:06+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-30640000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:12:06+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-30640000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:12:06+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-30640000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:12:06+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,47100000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:12:06+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.65
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:12:06+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,47100000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:12:06+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.65
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:12:06+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,47141146.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:12:06+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.65
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1534000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1534000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1534000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6153000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,34833000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,40986000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-39452000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,432000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-11000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,421000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-39031000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,9000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-39040000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-39040000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-39040000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,45900000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.81
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,45900000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.81
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,45899784.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.81
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,10000000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,10000000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,10000000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7621000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,41321000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,48942000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-38942000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,509000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-14000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,495000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-38447000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,12000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-38459000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-38459000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-38459000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,49300000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.78
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,49300000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.78
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,49602809.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:10:09+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.78
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q2,2018-04-01,2018-06-30,2018-08-07 17:18:59+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,19891000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q2,2018-04-01,2018-06-30,2018-08-07 17:18:59+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,19891000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q2,2018-04-01,2018-06-30,2018-08-07 17:18:59+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,19891000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q2,2018-04-01,2018-06-30,2018-08-07 17:18:59+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9489000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q2,2018-04-01,2018-06-30,2018-08-07 17:18:59+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,44734000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q2,2018-04-01,2018-06-30,2018-08-07 17:18:59+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,54223000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q2,2018-04-01,2018-06-30,2018-08-07 17:18:59+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-34332000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q2,2018-04-01,2018-06-30,2018-08-07 17:18:59+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,653000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q2,2018-04-01,2018-06-30,2018-08-07 17:18:59+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,7000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q2,2018-04-01,2018-06-30,2018-08-07 17:18:59+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,660000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q2,2018-04-01,2018-06-30,2018-08-07 17:18:59+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-33672000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q2,2018-04-01,2018-06-30,2018-08-07 17:18:59+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-17000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q2,2018-04-01,2018-06-30,2018-08-07 17:18:59+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-33655000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q2,2018-04-01,2018-06-30,2018-08-07 17:18:59+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-33655000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q2,2018-04-01,2018-06-30,2018-08-07 17:18:59+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-33655000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q2,2018-04-01,2018-06-30,2018-08-07 17:18:59+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,56100000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q2,2018-04-01,2018-06-30,2018-08-07 17:18:59+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.6
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q2,2018-04-01,2018-06-30,2018-08-07 17:18:59+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,56100000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q2,2018-04-01,2018-06-30,2018-08-07 17:18:59+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.6
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q2,2018-04-01,2018-06-30,2018-08-07 17:18:59+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,56089159.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q2,2018-04-01,2018-06-30,2018-08-07 17:18:59+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.6
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,478000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,478000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,478000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12966000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,36427000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,49393000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-49154000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1098000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-13000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1085000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-48069000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,14000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-48083000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-48083000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-48083000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,60900000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.79
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,60900000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.79
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,60586511.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 07:23:30+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.79
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,-33000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,-33000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-33000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,18771000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,38890000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,57661000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-57455000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2493000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1768000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-13000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-738000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-58193000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,17000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-58210000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-58210000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-58210000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,56800000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.97
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,56800000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.97
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,56799699.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.97
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,155000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,155000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,155000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,27103000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,37974000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,65077000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-64922000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2998000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1771000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1229000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-66151000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,10000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-66161000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-66161000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-66161000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,60700000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.09
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,60700000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.09
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,60856295.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:10:09+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.09
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,13149000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,13149000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1013000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1013000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,12136000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,25267000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,26270000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,51537000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-39401000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3093000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1137000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,10000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1946000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-41347000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,20000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-41367000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-41367000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-41367000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,61700000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.67
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,61700000.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.67
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,62092841.0
Karyopharm Therapeutics Inc,KPTI,549300J1VANRCNTYST87,0001503802,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:23:30+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.67
